GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Tax Provision

Swedish Orphan Biovitrum AB (OSTO:SOBI) Tax Provision : kr-470 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Tax Provision?

Swedish Orphan Biovitrum AB's tax provision for the three months ended in Mar. 2024 was kr-182 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was kr-470 Mil.

Swedish Orphan Biovitrum AB Tax Provision Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Tax Provision Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -942.00 -972.00 -616.00 -683.00 -546.00

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -258.00 -54.00 -22.00 -212.00 -182.00

Swedish Orphan Biovitrum AB Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-470 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Tax Provision
Comparable Companies
OSTO:BIOG B OSTO:SECARE OSTO:PROB OSTO:CRNO B XSAT:EQL OSTO:MOB OSTO:ORX OSTO:ENZY OSTO:VIVE XSAT:DICOT ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
SWOBY:USA BIOVF:USA SOBIs:UK 0MTD:UK B6E:Germany
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Website
https://www.sobi.com
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines